DRD2 and breast carcinoma: Furthermore, the integration of network pharmacology and molecular docking analyses revealed key targets associated with the anti-tumor effects of the pericarp, including PTGER3, DRD2, and ADORA2A, which present novel therapeutic targets for breast cancer treatment.